fda import alert green list glp-1 semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Launches 'Green List' to

(1) Inflammatory and autoimmune conditions have also been reported among associated causes, although the evidence is less consistent than for liver disease, renal disease, myeloid disease, and solid cancer

Supplementation with a combination of fish oil containing FAs and vitamins and minerals to males (W8-16) had no effect on POS-induced depressive-like behavior in the FST at W10-16 [122], while in females supplemented with choline, betaine, folic acid and vitamin B12 (P60-P186) the POS-induced depressive-like behavior was ameliorated in the FST at P165-186 [123]

Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional MRI: A PET/MR hybrid scanner study

Tested by independent laboratories for heavy metals, residual solvents, and endotoxins, in line with established limits

The role of upstream lipid and metabolic systems in alzheimers disease, parkinsons disease and dementias